Single dose of granulocyte colony stimulating factor in leukopenia after post-liver transplant.
Shayesteh AA, et al.Asian Journal of Pharmaceutical and Clinical Research 2014; 7: 47-49.
Aims
To evaluate the safety of Granulocyte colony stimulating factor (G-CSF) on leukopenia in early post liver transplantation (LTx) periods.
Interventions
The treatment group received 0.3 mg of G-CSF (PD - G-CSF) at the time of leukopenia
Participants
17 patients with a leukocyte count ≤3000/mm3 within the first 4 weeks after LTx
Outcomes
Outcomes measured were short-term patient’s and graft survival, hospital stay, acute cellular rejection (ACR), oropharyngeal candidiasis, active infections, day of maximum mycophenolate mofetil dosage achievement, ACR treatments episodes and the effect of G-CSF on leukocyte counts 24 hrs after administration.
Follow-up
4 weeks
CET Conclusions
This is a small trial (9 versus 8) that describes the used of GCSF for leucopenia post-liver transplant (first 4 weeks only). Unfortunately the immune suppression regimen is not described at all. The study is also too small to clearly prove any outcome other than a significant rise in white cell count within 24 hours of GCSF administration (0.3mg) compared to placebo. No difference could be seen in hospital stay (unclear if this was just post-transplant), microbiology cultures, oral candida, acute rejection or “day of desirable MMF dosage†(undefined). Generally the report does not contain enough detail, there is no power calculation and the method of randomisation is not described.
Data analysis
Per protocol analysis
Trial registration
None